CN107001378A - 吡咯并嘧啶化合物 - Google Patents

吡咯并嘧啶化合物 Download PDF

Info

Publication number
CN107001378A
CN107001378A CN201580066687.1A CN201580066687A CN107001378A CN 107001378 A CN107001378 A CN 107001378A CN 201580066687 A CN201580066687 A CN 201580066687A CN 107001378 A CN107001378 A CN 107001378A
Authority
CN
China
Prior art keywords
methyl
compound
alkyl
nhco
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201580066687.1A
Other languages
English (en)
Other versions
CN107001378B (zh
Inventor
祝力
校登明
胡远东
戴丽光
段小伟
孙颖慧
彭勇
孔凡胜
罗鸿
韩永信
杨玲
王善春
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Lianyungang Runzhong Pharmaceutical Co Ltd
Shouyao Holdings Beijing Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd, Lianyungang Runzhong Pharmaceutical Co Ltd, Shouyao Holdings Beijing Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority to CN201910594361.6A priority Critical patent/CN111018861B/zh
Publication of CN107001378A publication Critical patent/CN107001378A/zh
Application granted granted Critical
Publication of CN107001378B publication Critical patent/CN107001378B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

本申请涉及药物化学领域，具体涉及如式I所示的吡咯并嘧啶化合物、其立体异构体、其药学上可接受的盐。本申请还涉及制备如式I所示的吡咯并嘧啶化合物的方法、药物组合物、以及该化合物在治疗两面神激酶介导的疾病中的用途。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201580066687.1A 2014-12-16 2015-12-15 吡咯并嘧啶化合物 Active CN107001378B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910594361.6A CN111018861B (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2014107844612 2014-12-16
CN201410784461.2A CN105777754B (zh) 2014-12-16 2014-12-16 吡咯并嘧啶化合物
PCT/CN2015/097411 WO2016095805A1 (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910594361.6A Division CN111018861B (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物

Publications (2)

Publication Number Publication Date
CN107001378A true CN107001378A (zh) 2017-08-01
CN107001378B CN107001378B (zh) 2019-08-16

Family

ID=56125935

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201410784461.2A Active CN105777754B (zh) 2014-12-16 2014-12-16 吡咯并嘧啶化合物
CN201580066687.1A Active CN107001378B (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物
CN201910594361.6A Active CN111018861B (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201410784461.2A Active CN105777754B (zh) 2014-12-16 2014-12-16 吡咯并嘧啶化合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910594361.6A Active CN111018861B (zh) 2014-12-16 2015-12-15 吡咯并嘧啶化合物

Country Status (12)

Country Link
US (1) US10561657B2 (zh)
EP (1) EP3235819B1 (zh)
JP (2) JP6684803B2 (zh)
KR (1) KR102634308B1 (zh)
CN (3) CN105777754B (zh)
AU (1) AU2015366636B2 (zh)
CA (1) CA2971114C (zh)
DK (1) DK3235819T3 (zh)
ES (1) ES2847051T3 (zh)
HU (1) HUE053463T2 (zh)
RU (1) RU2701206C2 (zh)
WO (1) WO2016095805A1 (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108368115B (zh) * 2015-12-15 2020-01-03 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物的盐
CN107513069A (zh) * 2016-06-16 2017-12-26 正大天晴药业集团股份有限公司 手性吡咯并嘧啶化合物的制备方法
CN107759600A (zh) 2016-06-16 2018-03-06 正大天晴药业集团股份有限公司 作为jak抑制剂的吡咯并嘧啶化合物的结晶
CN107513067A (zh) * 2016-06-16 2017-12-26 北京赛林泰医药技术有限公司 含有取代环戊基的吡咯并嘧啶化合物
CN109651424B (zh) * 2017-10-11 2021-01-22 新发药业有限公司 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法
CN109867675B (zh) * 2017-12-01 2021-01-19 北京普祺医药科技有限公司 一种吡咯并嘧啶衍生的化合物、药物组合物以及其用途
JP2022515272A (ja) * 2018-12-24 2022-02-17 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド ピロロピリミジン化合物の治療的使用およびその固形医薬組成物
US20230133735A1 (en) * 2020-03-09 2023-05-04 Chia Tai Tianqing Pharmaceutical Co. ,Ltd. Use of pyrrolopyrimidine compound for treating hemophagocytic syndrome
WO2021236139A1 (en) * 2020-05-21 2021-11-25 Concert Pharmaceuticals, Inc. Novel deuterated jak inhibitor and uses thereof
CN114085224A (zh) * 2020-08-25 2022-02-25 北京普祺医药科技有限公司 一种吡咯并嘧啶化合物的制备方法
EP4361152A1 (en) * 2021-06-21 2024-05-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Use of pyrrolopyrimidine compound and pharmaceutical composition thereof for treating chronic graft versus host disease
WO2023179547A1 (zh) * 2022-03-21 2023-09-28 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗中高危骨髓纤维化的用途
WO2024027790A1 (zh) * 2022-08-04 2024-02-08 正大天晴药业集团股份有限公司 吡咯并嘧啶化合物治疗急性移植物抗宿主病的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8741912B2 (en) 2006-04-05 2014-06-03 Vertex Pharmaceuticals Incorporated Deazapurines useful as inhibitors of Janus kinases
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
CN102596960B (zh) * 2009-10-09 2016-01-20 因西特控股公司 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物
AU2011240808B2 (en) * 2010-04-14 2015-01-22 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of JAK kinases
EP2785184B1 (en) * 2011-11-30 2020-06-10 Emory University Compositions comprising jak inhibitors and haart drugs for use in the prevention or treatment of hiv
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
CN104725380B (zh) * 2013-12-18 2019-06-28 康塞特医药品有限公司 卢索替尼的氘代衍生物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101448826A (zh) * 2005-12-13 2009-06-03 因塞特公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡咯和吡咯并[2,3-b]嘧啶
CN102026999A (zh) * 2008-03-11 2011-04-20 因塞特公司 作为jak抑制剂的氮杂环丁烷和环丁烷衍生物
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
CN105218548A (zh) * 2014-06-09 2016-01-06 上海海和药物研究开发有限公司 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途

Also Published As

Publication number Publication date
US10561657B2 (en) 2020-02-18
JP2017537950A (ja) 2017-12-21
RU2017122824A (ru) 2019-01-18
JP2020105206A (ja) 2020-07-09
CN111018861A (zh) 2020-04-17
AU2015366636B2 (en) 2020-03-12
CA2971114A1 (en) 2016-06-23
RU2017122824A3 (zh) 2019-03-28
EP3235819A1 (en) 2017-10-25
RU2701206C2 (ru) 2019-09-25
DK3235819T3 (da) 2020-12-07
JP6684803B2 (ja) 2020-04-22
CN107001378B (zh) 2019-08-16
EP3235819A4 (en) 2017-11-01
CA2971114C (en) 2023-03-21
CN111018861B (zh) 2021-11-19
EP3235819B1 (en) 2020-11-18
US20190201403A1 (en) 2019-07-04
AU2015366636A1 (en) 2017-07-27
WO2016095805A1 (zh) 2016-06-23
CN105777754B (zh) 2019-07-26
KR20170095310A (ko) 2017-08-22
HUE053463T2 (hu) 2021-06-28
CN105777754A (zh) 2016-07-20
KR102634308B1 (ko) 2024-02-06
ES2847051T3 (es) 2021-07-30

Similar Documents

Publication Publication Date Title
CN107001378B (zh) 吡咯并嘧啶化合物
JP6832914B2 (ja) Ｍａｇｌ阻害薬としての１，１，１−トリフルオロ−３−ヒドロキシプロパン−２−イルカルバマート誘導体および１，１，１−トリフルオロ−４−ヒドロキシブタン−２−イルカルバマート誘導体
CN108699032A (zh) 多环tlr7/8拮抗剂及其在治疗免疫失调中的用途
JP2017518276A (ja) ブルトン型チロシンキナーゼ（ｂｔｋ）インヒビターとしての多フルオロ置換化合物
CN106986869A (zh) 用于抗病毒治疗的化合物和方法
CN110256440A (zh) 酞嗪异噁唑烷氧基衍生物、其制备方法、药物组合物和用途
CN102118969A (zh) 组胺h4受体的二氨基吡啶、二氨基嘧啶和二氨基哒嗪调节剂
BR112019014688A2 (pt) Derivados de carbamato de 1,1,1-trifluoro-3-hidroxipropan-2-il como inibidores de magl
CN113631557B (zh) Jak激酶抑制剂及其制备方法和在医药领域的应用
JP2022526295A (ja) キノリンおよびキナゾリン化合物およびその使用方法
EP3828174A1 (en) Pyridazinone derivative
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物
WO2022094400A1 (en) Bicyclic compounds and uses thereof for the treatment of diseases
TW202019406A (zh) 經取代四氫環戊[c]吡咯、經取代二氫吡咯，其類似物及使用其之方法
JP2019510053A (ja) シクロフィリンの阻害のための化合物及びその使用
CN109476638A (zh) 吡唑衍生物、其组合物及治疗用途
WO2023215377A1 (en) Methods of treating neuroinflammatory conditions
TW202200565A (zh) 抗病毒性1,3-二氧代茚化合物
TW202333663A (zh) Rxfp1促效劑
CN113082023A (zh) P2x3抑制剂和p2x4抑制剂的药物组合及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right
TA01 Transfer of patent application right

Effective date of registration: 20190529

Address after: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Applicant after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Address before: 222062 Yuzhou South Road, Haizhou District, Lianyungang, Jiangsu 369

Applicant before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Applicant before: Beijing Centaurus Biopharma Technology Co., Ltd.

Applicant before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

GR01 Patent grant
GR01 Patent grant
CP02 Change in the address of a patent holder
CP02 Change in the address of a patent holder

Address after: 222062 No. 369 Yuzhou South Road, Lianyungang City, Jiangsu Province

Co-patentee after: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Patentee after: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee after: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

Address before: 222062, No. 369, Yu Nan Road, Haizhou District, Jiangsu, Lianyungang

Co-patentee before: Capital Pharmaceutical Holdings (Beijing) Co., Ltd.

Patentee before: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Co-patentee before: Lianyungang Runzhong Pharmaceutical Co.,Ltd.

CP01 Change in the name or title of a patent holder
CP01 Change in the name or title of a patent holder

Address after: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee after: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Patentee after: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.

Address before: No. 369, Yuzhou South Road, Lianyungang, Jiangsu Province

Patentee before: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd.

Patentee before: Shouyao holding (Beijing) Co.,Ltd.

Patentee before: LIANYUNGANG RUNZHONG PHARMACEUTICAL Co.,Ltd.